NeuroMab™ Anti-TLR4/MD-2 BBB Shuttle Antibody(NRZP-1022-ZP2662)

Fig.1 is a graph depicting the binding of a murine monoclonal antibody, referred to here in as “7E3”, to the TLR4/MD-2 complex.

Specificity of binding is shown by flow cytometry using mock transfected or TLR4/MD-2 transfected cells.

Fig.2 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production in TLR4/MD-2 transfected HEK 293 cells by the monoclonal antibody mu7E3.

Specificity of binding is shown by flow cytometry using mock transfected or TLR4/MD-2 transfected cells.

Fig.3 depicting inhibition of LPS-induced IL-6 production in human whole blood by the monoclonal antibody mu7E3.

Specificity of binding is shown by flow cytometry using mock transfected or TLR4/MD-2 transfected cells.

Fig.4 is a series of graphs depicting the specificity of the mu7E3 monoclonal antibody for the TLR4/MD-2 complex.

The specificity of the mu7E3 antibody is shown by flow cytometry analysis of HEK 293 cells transiently transfected with either mock vector (Panel A), human TLR4 (Panel B), human TLR4 and human MD-2 (Panel C), rabbit TLR4 and rabbit MD-2 (Panel D).

Fig.5 is a graph illustrating that the VH and VL nucleotide sequence of mu7E3 expressed as a chimeric MAb (“chimeric 7E3”) is capable of binding specifically to the human TLR4/MD-2 complex on the surface of transfected CHO cells.

The specificity of the mu7E3 antibody is shown by flow cytometry analysis of HEK 293 cells transiently transfected with either mock vector (Panel A), human TLR4 (Panel B), human TLR4 and human MD-2 (Panel C), rabbit TLR4 and rabbit MD-2 (Panel D).

Fig.6 is a graph depicting inhibition of lipopolysaccharide (LPS)-induced IL-8 production in TLR4/MD-2 transfected HEK 293 cells by the chimeric 7E3 MAb.

Cells were incubated with chimeric 7E3 or an isotype matched MAb control at the indicated concentrations and subsequently incubated with LPS (15 ng/ml). IL-8 levels were assessed 16 hours post LPS-treatment.